(NP (JJ Steroid-resistant) (NN asthma) (. .))
(NP (NP (JJ Cellular) (NNS mechanisms)) (VP (VBG contributing) (PP (TO to) (NP (NP (JJ inadequate) (NN response)) (PP (TO to) (NP (NN glucocorticoid) (NN therapy)))))) (. .))
(S (NP-SBJ (DT The) (JJ current) (NN study)) (VP (VBD examined) (SBAR (IN whether) (S (NP-SBJ (NP (NNS alterations)) (PP (IN in) (NP (NP (NP (NN glucocorticoid) (NN receptor)) (PRN (-LRB- -LRB-) (NP (NN GR)) (-RRB- -RRB-))) (NN binding)))) (VP (VBP contribute) (PP (TO to) (NP (NP (JJ poor) (NN response)) (PP (TO to) (NP (NP (NN glucocorticoid) (NN therapy)) (PP (IN in) (NP (NN asthma))))))))))) (. .))
(S (NP-SBJ-19 (NP (CD 29) (NN asthma) (NNS patients)) (PP (IN with) (NP (NP (NP (NP (NP (VBN forced) (JJ expiratory) (NN volume)) (PP (IN in) (NP (CD 1) (NN s)))) (PRN (-LRB- -LRB-) (NP (NN FEV1)) (-RRB- -RRB-))) (NP (QP (JJR &lt;) (CD 70)) (NN %))) (VP (VBN predicted) (NP (-NONE- *)))))) (VP (VBD were) (VP (VBN studied) (NP (-NONE- *-19)))) (. .))
(S (NP-SBJ-20 (NNS Patients)) (VP (VBD were) (VP-COOD (VP (VBN classified) (NP (-NONE- *-20)) (PP (IN as) (ADJP-102 (ADJP (NN steroid) (JJ sensitive)) (PRN (-LRB- -LRB-) (ADJP (JJ SS)) (-RRB- -RRB-)))) (SBAR-103 (IN if) (S (NP-SBJ (PRP$ their) (NN morning) (NN FEV1)) (VP (VBD increased) (NP (QP (RBR &gt;) (CD 30)) (NN %)) (PP-TMP (IN after) (NP (NP (DT a) (JJ 1-wk) (NN course)) (PP (IN of) (NP (NP (JJ oral) (NN prednisone)) (NP (CD 20) (NN mg)) (ADVP (RB twice) (RB daily)))))))))) (CC and) (VP (ADJP=102 (ADJP (NN steroid) (JJ resistant)) (PRN (-LRB- -LRB-) (ADJP (JJ SR)) (-RRB- -RRB-))) (SBAR=103 (IN if) (S (NP-SBJ-21 (PRP they)) (VP (VBD failed) (S (NP-SBJ (-NONE- *-21)) (VP (TO to) (VP (VB increase) (NP (QP (RBR &gt;) (CD 15)) (NN %))))))))))) (. .))
(S (NP-SBJ-22 (NP (NN PBMC)) (VP (VBN obtained) (NP (-NONE- *)) (PP (IN from) (NP-COOD (NP (NP (DT these) (CD two) (NNS groups)) (, ,) (NP-COOD (NP (CD 17) (JJ SR)) (CC and) (NP (CD 12) (JJ SS))) (, ,)) (CONJP (RB as) (RB well) (IN as)) (NP (CD 12) (JJ normal) (NNS controls)))))) (VP (VBD were) (VP (VBN analyzed) (NP (-NONE- *-22)))) (. .))
(S (S (NP-SBJ (JJ SR) (NNS patients)) (VP (VBD had) (NP (CD two) (JJ distinguishable) (NN GR) (NN binding) (NNS abnormalities))) (: :)) (S (NP-SBJ-104 (NP (CD 15)) (PP (IN of) (NP (DT the) (CD 17) (JJ SR) (NNS patients)))) (VP (VBD demonstrated) (NP (DT a) (ADJP (RB significantly) (VBN reduced)) (NN GR) (NN binding) (NN affinity)) (, ,) (SBAR (IN as) (S (NP-SBJ-105 (-NONE- *-104)) (VP (VBN compared) (NP (-NONE- *-105)) (PP (IN with) (NP-COOD (NP (NP (JJ SS) (NNS patients)) (PRN (-LRB- -LRB-) (S (NP-SBJ (NN P)) (VP (JJ =) (NP-PRD (CD 0.0001)))) (-RRB- -RRB-))) (CC and) (NP (NP (JJ normal) (NNS controls)) (PRN (-LRB- -LRB-) (S (NP-SBJ (NN P)) (VP (JJ =) (NP-PRD (CD 0.0001)))) (-RRB- -RRB-)))))))))) (. .))
(S (NP-SBJ-23 (DT This) (NN defect)) (VP-COOD (VP (VBD was) (VP (JJ localized) (NP (-NONE- *-23)) (PP (TO to) (NP (NN T) (NNS cells))))) (CC and) (VP (VBD reverted) (PP (TO to) (NP (JJ normal))) (PP-TMP (IN after) (NP (NP (CD 48) (NN h)) (PP (IN in) (NP (NN culture) (NNS media))))))) (. .))
(S (ADVP (RB However)) (, ,) (NP-SBJ (NP (NN incubation)) (PP (IN with) (NP (NP (DT a) (NN combination)) (PP (IN of) (NP-COOD (NP (NN IL-2)) (CC and) (NP (NN IL-4))))))) (VP (VBD sustained) (NP (DT this) (NN abnormality))) (. .))
(S (NP-SBJ (DT The) (JJ other) (CD two) (JJ SR) (NNS patients)) (VP (VBD had) (NP (NP (DT an) (ADJP (RB abnormally) (JJ low)) (NN GR) (NN number)) (PP (IN with) (NP (NP (JJ normal) (NN binding) (NN affinity)) (SBAR (WHNP-24 (WDT that)) (S (NP-SBJ (-NONE- *T*-24)) (VP (VBD was) (RB not) (ADJP-PRD (VBN limited) (PP (TO to) (NP (NN T) (NNS cells))))))))))) (. .))
(S (ADVP (RB Furthermore)) (, ,) (NP-SBJ-26 (NN GR) (NN number)) (VP (VBD failed) (S (NP-SBJ (-NONE- *-26)) (VP (TO to) (VP (VB normalize) (PP-TMP (IN after) (NP (NP (NN incubation)) (PP (IN in) (NP-COOD (NP (NP (NNS media)) (ADVP (RB alone))) (CC or) (NP-COOD (NP (NN IL-2)) (CC and) (NP (NN IL-4))))))))))) (. .))
(S (ADVP (RB Therefore)) (, ,) (NP-SBJ (JJ SR) (NN asthma)) (VP (MD may) (VP (VB be) (PP-PRD (JJ due) (TO to) (NP (NP (QP (JJR more) (IN than) (CD one)) (NN abnormality)) (, ,) (NP-COOD (NP (NP (DT the) (NN majority)) (ADJP (JJ related) (PP (TO to) (NP (NP (DT a) (JJ reversible) (JJ cytokine-induced) (NN reduction)) (PP (IN in) (NP (NN GR) (NN binding) (NN affinity))))))) (CC and) (NP (NP (DT the) (JJ second)) (ADJP (JJ related) (PP (TO to) (NP (NP (DT an) (JJ irreversible) (NN reduction)) (PP (IN in) (NP (NN GR) (NN number)))))))))))) (. .))
(S (NP-SBJ (DT These) (NNS findings)) (VP (MD may) (VP (VB have) (NP (JJ important) (NNS implications)) (PP (IN for) (NP (NP (DT the) (NN design)) (PP (IN of) (NP (NP (JJ alternative) (NN treatment) (NNS approaches)) (PP (IN for) (NP (JJ recalcitrant) (NN asthma))))))))) (. .))
